1. Volume 61, Issue 6, Pages 1229-1238 (June 2012)
Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer 
Robert Rosenblatt, Amir Sherif, Erkki Rintala, Rolf Wahlqvist, Anders Ullén, Sten Nilsson, Per-Uno Malmström 
European Urology 
Volume 61, Issue 6, Pages (June 2012)
DOI: /j.eururo
Copyright © 2011 European Association of Urology Terms and Conditions

2. Fig. 1
Consolidated Standards of Reporting Trials (CONSORT) flowchart showing the stepwise selection of the eligible 449 patients from the original 620.
NCT=Nordic Cystectomy Trial.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

3. Fig. 2
Percentage of completely downstaged tumours stratified over the clinical T stages and study arms. A significant increase in complete downstaging was observed in the neoadjuvant arm when comparing all tumours (p=0.006) and cT3 tumours (p=0.014).
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

4. Fig. 3
Percentage of noninvasive downstaged tumours stratified over clinical T stages and study arms. The neoadjuvant arm revealed a significant increase in noninvasive downstaging when comparing study arms for all tumours (p=0.001), clinical T2 tumours (p=0.024), and clinical T3 tumours (p=0.005).
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

5. Fig. 4
Percentage of organ-confined tumours stratified over clinical T stages and study arms. Clinical T3 tumours were the only group in which a significant difference appeared between the study arms, revealing a 16.9% increase in organ-confined tumours in favour of the neoadjuvant arm (p=0.009).
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

6. Fig. 5
Overall survival of 449 cystectomised patients stratified into four groups. Patients with completely downstaged tumours in the neoadjuvant arm (blue) exhibited an 88.2% 5-yr survival rate compared with 57.1% in patients with completely downstaged tumours in the control arm (green) (p=0.001). Nondownstaged tumours in the neoadjuvant (yellow) and in the control arm (orange) indicated nonsignificant survival differences.
CD=complete downstaging; Ctrl=control; NAC=neoadjuvant chemotherapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

7. Fig. 6
Overall survival of 449 cystectomised patients stratified into four patient groups. Patients with noninvasive downstaging (NID) tumours in neoadjuvant arm (blue) had a 5-yr survival of 83% compared with 65% in NID controls (green) (p=0.018). Patients with non-NID tumours in the neoadjuvant arm (yellow) and non-NID controls (orange) showed nonsignificant survival differences.
Ctrl=control; NAC=neoadjuvant chemotherapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

8. Fig. 7
Overall survival of 449 cystectomised patients stratified into four groups. Patients with organ-confined (OC) tumours in the neoadjuvant arm (blue) exhibited a 77.5% 5-yr survival compared with 64.6% in patients with OC in the control arm (green) (p=0.005). No statistical difference in survival was observed between patients with non–organ-confined (NOC) tumours in the neoadjuvant arm (yellow) and NOC tumours in the control arm (orange).
Ctrl=control; NAC=neoadjuvant chemotherapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions